Medical

Leyden Labs has published results from pre-clinical and clinical studies of its PanFlu (CR9114) intranasal antibody in the journal Science Translational Medicine. According to the company, two Phase 1 trials that enrolled a total of 143… Read more . . .

ENA Respiratory has announced the initiation of the Phase 2 POSITS trial of its INNA-051 once-weekly antiviral nasal powder. In April 2025, ENA announced that researchers at the University of Maryland would conduct a Phase… Read more . . .

Nasus Pharma said that data from the first cohort dosed in its Phase 2 clinical study of NS002 epinephrine nasal powder demonstrate greater mean peak plasma concentration and faster time to peak concentration for the… Read more . . .

Agomab Therapeutics has announced interim results from a Phase 1 study of AGMB-447 inhaled ALK5 inhibitor that was initiated in 2023. The data from the SAD/MAD portion of the study in 108 healthy participants found… Read more . . .

Krystal Biotech has announced results from the highest dose cohort of its Phase 1 CORAL-1 trial of KB407 gene therapy that confirm CFTR expression in 6 of 7 cystic fibrosis patients who received 4 administrations… Read more . . .

Pulmocide has announced the termination of the Opera-T Phase 3 study of opelconazole inhalation suspension in patients with invasive pulmonary aspergillosis. According to the company, an interim analysis found that patients receiving opelconazole had poorer… Read more . . .

Florida-based inhaled drug developer Transpire Bio has announced the initiation of a Phase 1 trial of a synthetic inhaled cannabidiol formulation, which the company is developing for Parkinson’s disease psychosis and for other central nervous… Read more . . .

According to SoftOx Solutions, the Danish Medicines Agency has approved the company’s application for a Phase 2a trial of SoftOx hypochlorous acid inhalation solution in healthy volunteers and in patients with cystic fibrosis. SoftOx announced… Read more . . .

Vistagen has announced that the Phase 3 PALISADE-3 study of intranasal fasedienol for the treatment of social anxiety disorder failed to meet its primary endpoint, with fasedienol failing to demonstrate a statistically significant reduction of… Read more . . .